We are Responsible for Making the World a Better Place
Driven by science, guided by responsibility, we create solutions that improve lives, strengthen healthcare systems, and shape a healthier future for communities worldwide.
Learn More
Driven by science, guided by responsibility, we create solutions that improve lives, strengthen healthcare systems, and shape a healthier future for communities worldwide.
Learn More
Our aim is to provide good health to people around the globe, by manufacturing high quality and affordable generic formulations. We have cutting edge manufacturing facilities that have led to the successful commercialisation of 19.4 million Injectables and approved products in 50+ countries, with unparalleled customer satisfaction.
Country Approvals
Injectables Commercialized
Aligned Manufacturing
We are an innovative pharmaceutical company with an active mission to transform healthcare through bold pursuits in science by combining excellence in research, development, manufacturing, marketing and supply chain operations.
We are committed to improving lives through high-quality, effective and affordable medications. We strive to improve patient outcomes by advancing innovations in drug-discovery and commercialisation.
At Jodas, “ One Step Better” is more than just a tagline. It reflects our dedication to providing uncompromising quality. Our 'quality first' approach ensures excellence in every product, process, decision and action.
We bring together a team of excellent research and development professionals who are committed to developing high quality, effective and affordable pharmaceutical formulations that meet the evolving needs of the Global market
We are driven to improve global healthcare and patient well-being. Our skilled team of doctors and scientists are committed to develop high-quality pharmaceutical innovations contributing to a healthier world.
Our journey reflects our evolution into a globally trusted pharmaceutical company advancing through innovation, quality, research and excellence.
Jodas Expoim began its journey as a speciality generic Pharmaceutical in October 2006. Russia was our first commercial market and we commenced our operation with Cephalosporin Antibiotics,initially manufacturing approximately 5-10 Million units. Guided by our philosophy of “One step better” we have remained committed to deliver innovative, high-quality and effective generic formulations for the past two decades.
We expanded our establishments by opening a subsidiary and regional office in Russia. This milestone contributed exponentially to the company’s growth, enhancing regional operations and accelerating international growth.
We laid the foundation for our Greenfield Global Manufacturing facility in Hyderabad. Establishing our own manufacturing facility strengthened quality control and marked a major transition from third party manufacturing. Hyderabad, being the ‘Vaccine Hub of India’ also made it a geographically ideal location for this milestone.
We expanded our presence to over 50 cities across Russia while actively focusing on hospital supplies. During this phase, we also secured 68 product registrations in Russia, which significantly broadened our portfolio and market reach. These milestones strengthened our presence in Russia and established Jodas as a top pharmaceutical partner.
We completed multiple phases of expansion across all our manufacturing units, significantly enhancing our production capabilities and operational excellence. In 2017, we achieved the prestigious EU GMP certification, reaffirming our commitment to global quality standards. As EU GMP is recognized by regulatory authorities in numerous countries, the certification unlocked direct access to new global markets and created opportunities for broader international expansion. It marked a significant step in positioning Jodas Expoim as a globally trusted pharmaceutical manufacturer.
We secured the SFDA (Saudi Food and Drug Authority) approval in 2019, which was a significant milestone in our journey into the Middle East. Building on our EU GMP-compliant manufacturing standards, we completed our UAE registration, enabling commercial operations across the MENA (Middle East and North Africa) region. In 2020, during the COVID-19 pandemic, we developed our transportation and packaging processes and complied with global laws and regulations to ensure uninterrupted product availability and supply in the market. Despite the unprecedented global challenges, Jodas was committed to delivering high-quality medicines to patients across international markets.
We received the reissuance of Russian GMP certification for all manufacturing blocks. This ensured uninterrupted business operations and continued access to the Russian market. The certification reinforced our commitment to maintaining the highest quality standards and strengthened our long-standing presence in the region.
Our demand in the global market had multiplied leading to a significant global milestone i.e Global Recognition. We had 250+ approved molecules and an expanding presence across 25+ countries. During this phase, our strongest markets included Russia, the EAEU region, LATAM, MENA, Saudi Arabia, and Africa. We also expanded our manufacturing capabilities into Russia and the CIS region, improving efficiency and placing ourselves as one of Russia's top pharmaceutical companies. This period improved our regulatory footprint, gave us access to key international markets, and marked a new phase of global recognition and growth for Jodas Expoim.
We strengthened our global presence by securing ANVISA (Brazil) approvals for our Oncology, General Injectable and Cephalosporin manufacturing blocks. We also expanded our international compliance with TMDA (Tanzania) approvals and the reissuance of GMP certifications from EAEU and European authorities across all our manufacturing blocks. During this period, we launched our contract media and Oncology products in the domestic market to address the growing demand for these specialised therapies. Looking ahead, we remain committed to introducing new products every year, as we continue to expand into more international markets.
We offer a diverse range of high-quality pharmaceutical products developed by our highly skilled R&D professionals and advanced manufacturing technologies.
Research and Development is the fulcrum of a Pharmaceutical company, and our attention to the finest details of R & D reflects in our portfolio as well as in our day-to-day activities.
Our leadership team combines over 70 years of extensive experience across the pharmaceutical industry. Their proven leadership, scientific experience and insight helps to strengthen our legacy of innovation, quality and global excellence.
Chief Managing Director - Management
Managing Director - Management
Deputy Chief Managing Director - Management
Senior VP Operations
Sr. Manager – Company Secretary & Legal Affairs
General Manager - Regulatory Affairs
Vice President – Supply Chain Management
CFO – Finance & Accounts
General Manager - Operations
General Manager - QC
President - FR&D
Vice President - FR&D
Senior General Manager, API
Principal Scientist I - AR&D
Sr. Scientist I - QA
Asst. Vice President - Biotechnology
Lung cancer stands as a leading cause of cancer-related deaths globally, characterized by high mortality rates due to frequent late-stage detection, as early phases are often asymptomatic.
Read more..
The blog "A Deeper Dive into Understanding Breast Cancer" explains the disease's development, risk factors, and treatment options. Breast cancer begins in the milk ducts or lobules and can spread if untreated, becoming life-threatening.
Read more..
Cancer cases in India are expected to rise 12.8% by 2025 due to mutations in genes that impact, protein expression, and alter cells. Chimeric Antigen Receptor T cells (CAR-T) are genetically modified fusion proteins that can be expressed and transfused into patients.
Read more..
